
June 24 (Reuters) - OS Therapies Inc OSTX.A:
OS THERAPIES RECEIVES POSITIVE FDA MEETING FEEDBACK ON REGULATORY PATHWAY FOR ACCELERATED APPROVAL OF OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PEDIATRIC LUNG METASTATIC OSTEOSARCOMA
OS THERAPIES INC - REQUESTS END OF PHASE 2 MEETING AND BTD
OS THERAPIES INC - END OF PHASE 2 MEETING EXPECTED IN Q3 2025